Key result
18F-FDG PET/CT SUV2 after neoadjuvant chemotherapy accurately predicted histologic response in pediatric sarcoma with 100% sensitivity and 91.67% specificity.
Why the study?
The study was conducted to highlight the role of FDG PET/CT in assessing tumor response to preoperative chemotherapy in pediatric sarcoma.
Does 18F-FDG PET/CT accurately assess tumor response to preoperative chemotherapy in pediatric sarcoma?
Observational (n=18)
No
Does 18F-FDG PET/CT accurately assess tumor response to preoperative chemotherapy in pediatric sarcoma?
18F-FDG PET/CT is a highly accurate, non-invasive imaging tool for assessing the histologic response to preoperative chemotherapy in pediatric sarcoma, outperforming conventional size-based morphological criteria.
Answers are grounded in this paper and cite their sources.
May support PET/CT for response assessment in pediatric sarcoma; hypothesis-generating pending prospective validation.
The aim of this retrospective study was to highlight the role of FDG PET/CT in the assessment of tumor response to preoperative chemotherapy in pediatric sarcoma. Eighteen patients were included in our study: 13 patients were males and 5 were females ranging between 1 and 18 years with a mean age of 13.3 years. The patients had pathologically proven osseous or soft tissue sarcoma. All patients underwent sequential 18F-FDG PET/CT before (PET-CT1) and after (PET-CT2) neoadjuvant chemotherapy. Maximum standardized uptake value (SUVmax) was measured in the primary lesion on PET/CT1 (SUV1) and PET/CT2 (SUV2). After surgery, the effects of neoadjuvant chemotherapy were evaluated histopathologically: ≥ 90% necrosis indicated was considered a good response and < 90% necrosis was considered a poor response. The correlation between SUV2 and the histologic response was assessed. The sensitivity, specificity, positive predictive value, and negative predictive value of SUV2 for assessment of treatment response were 100%, 91.67%, 85.71%, and 100%, respectively. The overall accuracy was found to be 98.3%. 18F-FDG PET/CT provides a reliable non-invasive diagnostic tool in assessment of response to preoperative chemotherapy in pediatric sarcoma.
No takes yet. Share an insight, caveat, or question.
Rashad et al. (2019) conducted an observational in Pediatric sarcoma (n=18). 18F-FDG PET/CT (SUV2) vs. Histopathological response (<90% vs ≥90% necrosis) was evaluated on Diagnostic accuracy of SUV2 for assessment of treatment response (p=<0.001). 18F-FDG PET/CT SUV2 after neoadjuvant chemotherapy accurately predicted histologic response in pediatric sarcoma with 100% sensitivity and 91.67% specificity.
Synapse has enriched 10 related papers. Consider them for comparative context: